Related Experiment Video

Updated: Jul 7, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Apoptotic blocks and chemotherapy resistance: strategies to identify Bcl-2 protein signatures

Ozgur Gul1, Huveyda Basaga, Ozgur Kutuk

  • 1Biological Sciences and Bioengineering Program, Sabanci University.

Briefings in Functional Genomics & Proteomics
|February 20, 2008
PubMed

Insights

Chemotherapy resistance in epithelial cancers is poorly understood. This review focuses on the Bcl-2 protein network and apoptotic defects contributing to resistance, crucial for developing effective cancer therapeutics.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Pathways

Background:

  • Chemotherapy resistance is a significant challenge in cancer treatment, particularly in epithelial cancers.
  • The molecular basis of chemotherapy resistance is not fully elucidated.
  • Mitochondrial apoptosis is a key pathway targeted by many chemotherapies.

Purpose of the Study:

  • To review strategies for identifying apoptotic defects causing chemotherapy resistance.
  • To focus on the role of the Bcl-2 protein network in chemotherapy resistance.

Main Methods:

  • Literature review of studies investigating chemotherapy resistance mechanisms.
  • Analysis of the Bcl-2 protein family's role in mitochondrial apoptosis.
  • Examination of apoptotic defects linked to therapeutic failure.

Main Results:

  • The Bcl-2 protein network plays a critical role in regulating mitochondrial apoptosis.
  • Defects in apoptotic pathways, particularly involving Bcl-2 proteins, are frequently associated with chemotherapy resistance.
  • Understanding these defects is key to overcoming resistance.

Conclusions:

  • Targeting the Bcl-2 protein network offers potential strategies to overcome chemotherapy resistance.
  • Further research into apoptotic defects is essential for improving cancer therapy efficacy.
  • Identifying specific Bcl-2 interactions can guide the development of novel therapeutic approaches.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...